Discure Technologies Overview
Discure Technologies developed a minimally invasive device to treat and reverse degenerative disc disease, reducing pain and restoring functionality to the patient. The system is designed to eliminate the need for invasive surgery and reduce the use of opioids.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Discure Technologies raises $16 million for degenerative disc disease treatment | CTech
Discure Technologies has successfully completed $16 million in financing to advance its treatment for degenerative disc disease (DDD). The funding includes $11 million from an oversubscribed Series A round and $5 million from a SAFE raise. The Series A round was led by BOLD Capital Partners, Supernova Invest, and Sanara Capital, with participation from U.S. hospital networks, orthopedic surgeons, and medtech investors. The investment will accelerate the companys growth, allowing it to make key hires and fully fund its First-in-Human clinical study in Canada and Italy. Discures novel approach aims to shift the paradigm from symptom management to regenerating the disc.
InvestmentPartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $21M |
| Last funding | $11M |
| Stage | A |
| Rounds | 3 |
| Investors | 7 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | discuremd.com |
Locations
Medinat HaYehudim Street 85, Herzliya, Israel
Photos & Videos
1 item(s)
